AbCellera is a pioneering biotechnology company based in Vancouver, British Columbia. As a valued member of our network, AbCellera brings deep expertise in antibody discovery and a collaborative spirit that is helping to reshape the landscape of therapeutic development. Their integrated technology platform searches, decodes, and analyzes natural immune responses to identify high-potential antibody candidates with speed and precision.

With a strong commitment to scientific excellence and innovation, AbCellera partners with organizations around the world to accelerate the development of new medicines. Their work spans early discovery to investigational new drug (IND) filing, with a proven track record that includes one of the first antibody therapies authorized for emergency use during the COVID-19 pandemic.

We’re proud to count AbCellera among our members, and we applaud their continued contributions to advancing health research and development in Canada and beyond.